Is there a future for the use of left ventricular assist devices in Duchenne muscular dystrophy?. Issue 4 (27th November 2020)

• Record Type: Journal Article
• Authors: Hayes, Emily A.; Nandi, Deipanjan
• Other Names: Birnkant David guestEditor.; Cripe Linda guestEditor.
• Is Part Of: Pediatric pulmonology. Volume 56:Issue 4(2021)
• Page Start: 753
• Page End: 759
• Publication Date: 2020-11-27
• Subjects: cardiomyopathy -- Duchenne muscular dystrophy -- heart failure -- ventricular assist device; Pediatric respiratory diseases -- Periodicals; Pediatrics -- Periodicals; 618.922
• DOI: 10.1002/ppul.25181
• Languages: English
• ISSNs: 8755-6863

Abstract

Abstract: Duchenne muscular dystrophy (DMD) is the most common form of childhood muscular dystrophy resulting in progressive muscle wasting and weakness. With advancements in respiratory care and the use of glucocorticoids, cardiomyopathy has surpassed respiratory compromise as the leading cause of morbidity and mortality in this patient population. As muscular dystrophy remains a relative contraindication to heart transplantation, end‐stage heart failure management represents a major therapeutic challenge. Long‐term left ventricular assist device (LVAD) therapy has emerged as a promising management strategy to improve the survival and quality of life in DMD cardiomyopathy. Preoperative planning, optimal patient selection, aggressive postoperative rehabilitation, and continued discussion of goals of care are critical considerations for the appropriate use of LVAD in DMD patients with cardiomyopathy.